New anti-tuberculosis therapies

Bibliography

• WORLD HEALTH ORGANIZATION: Global tuberculosis control: surveillance, planning, financing WHO report (2006).
   Google Scholar
• WORLD HEALTH ORGANIZATION: Global tuberculosis control: surveillance, planning, financing WHO report (2007).
   Google Scholar
• WORLD HEALTH ORGANIZATION: Treatment of tuberculosis: guidelines for National Programmes. Third Edition (2003).
   Google Scholar
• ATTARAN A: An immeasurable crisis? A criticism of the millennium development goals and why they cannot be measured. PLoS Med. (2005) 2:e318.
   PubMed Web of Science ®Google Scholar
• CAMINERO JA: A tuberculosis guide for specialist physicians. International Union Against Tuberculosis and Lung Disease. Paris (2004).
   Google Scholar
• MEDICAL RESEARCH COUNCIL: Treatment of pulmonary tuberculosis with streptomycin and para-aminosalicylic acid. BMJ (1950) 2:1073-1085.
   Google Scholar
• MEDICAL RESEARCH COUNCIL: Various combinations of isoniazid with streptomycin or with PAS in the treatment of pulmonary tuberculosis. BMJ (1955) 1:435-445.
   Google Scholar
• TUBERCULOSIS CHEMOTHERAPY CENTRE MADRAS: A concurrent comparison of home and sanatorium treatment of pulmonary tuberculosis in South India. Bull. World Health Organ. (1959) 21:51-144.
   Google Scholar
• DOSTER B, MURRAY FJ, NEWMAN R, WOOLPERT SF: Ethambutol in the initial treatment of pulmonary tuberculosis. U.S. Public Health Service Tuberculosis Therapy Trials. Am. Rev. Respir. Dis. (1973) 107:177-190.
   PubMed Web of Science ®Google Scholar
• ISEMAN MD: Tuberculosis therapy: past, present and future. Eur. Respir. J. Suppl. (2002) 36:87s-94s.
   PubMedGoogle Scholar
• RIEDER HL: Interventions for tuberculosis control and elimination. International Union Against Tuberculosis and Lung Disease. Paris (2002).
   Google Scholar
• FOX W, ELLARD GA, MITCHISON DA: Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis unit. Int. J. Tuberc. Lung Dis. (1999) 3:S231-S279.
   PubMed Web of Science ®Google Scholar
• MITCHISON DA: The diagnosis and therapy of tuberculosis during the past 100 years. Am. J. Respir. Crit. Care Med. (2005) 171:699-706.
   PubMed Web of Science ®Google Scholar
• TUBERCULOSIS RESEARCH CENTRE: Shortening short course chemotherapy: a randomised clinical trial for treatment of smear positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Ind. J. Tub. (2002) 49:27-38.
   Google Scholar
• NUERMBERGER E, GROSSET J: Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur. J. Clin. Microbiol. Infect. Dis. (2004) 23:243-255.
   PubMed Web of Science ®Google Scholar
• McILLERON H, WASH P, BURGER A: Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob. Agents Chemother. (2006) 50:1170-1177.
   PubMed Web of Science ®Google Scholar
• DESTA Z, SOUKHOVA NV, FLOCKHART DA: Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob. Agents Chemother. (2001) 45:382-395.
   PubMed Web of Science ®Google Scholar
• GRANGE J, WINSTANLEY PA, DAVIES PD: Clinically significant drug interactions with antituberculosis agents. Drug Saf. (1994) 11:242-251.
   PubMed Web of Science ®Google Scholar
• GROSSET J, TRUFFOT-PERNOT C, LACROIX C, JI B: Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob. Agents Chemother. (1992) 36:548-551.
   PubMed Web of Science ®Google Scholar
• JINDANI A, DORE CJ, MITCHISON DA: Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am. J. Respir. Crit. Care Med. (2003) 167:1348-1354.
   PubMed Web of Science ®Google Scholar
• IMMANUEL C, GURUMURTHY P, RAMACHANDRAN G, VENKATESAN P, CHANDRASEKARAN V, PRABHAKAR R: Bioavailability of rifampicin following concomitant administration of ethambutol or isoniazid or pyrazinamide or a combination of the three drugs. Indian J. Med. Res. (2003) 118:109-114.
   PubMed Web of Science ®Google Scholar
• MITCHISON DA: The search for new sterilizing anti-tuberculosis drugs. Front. Biosci. (2004) 9:1059-1072.
   PubMed Web of Science ®Google Scholar
• DICK T: Dormant tubercle bacilli: the key to more effective TB chemotherapy? J. Antimicrob. Chemother. (2001) 47:117-118.
   PubMed Web of Science ®Google Scholar
• ZHANG Y: Persistent and dormant tubercle bacilli and latent tuberculosis. Front. Biosci. (2004) 9:1136-1156.
   PubMed Web of Science ®Google Scholar
• ZHANG Y: The magic bullets and tuberculosis drug targets. Annu. Rev. Pharmacol. Toxicol. (2005) 45:529-564.
   PubMed Web of Science ®Google Scholar
• DUNCAN K, BARRY CE: Prospects for new antitubercular drugs. Curr. Opin. Microbiol. (2004) 7:460-465.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, POST-MARTENS K, DENKIN S: New drug candidates and therapeutic targets for tuberculosis therapy. Drug Discov. Today (2006)11:21-27.
   PubMed Web of Science ®Google Scholar
• TROUILLER P, OLLIARO P, TORREELE E, ORBINSKI J, LAING R, FORD F: Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet (2002) 359:2188-2194.
   PubMed Web of Science ®Google Scholar
• GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT: Scientific blueprint for TB drug development. Tuberculosis (Edinb) (2001) 81(Suppl. 1):1-52.
   Google Scholar
• HAMPTON T: TB drug research picks up the pace. JAMA (2005) 293:2705-2707.
   PubMed Web of Science ®Google Scholar
• SMITH CV, SHARMA V, SACCHETTINI JC: TB drug discovery: addressing issues of persistence and resistance. Tuberculosis (Edinb) (2004) 84:45-55.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, AMZEL ML: Tuberculosis drug targets. Curr. Drug Targets (2002) 3:131-154.
   PubMed Web of Science ®Google Scholar
• GLICKMAN SW, RASIEL EB, HAMILTON CD, KUBATAEV A, SCHULMAN KA: A portfolio model of drug development for tuberculosis. Science (2006) 311:1246-1247.
   PubMed Web of Science ®Google Scholar
• MDLULI K, SPIGELMAN M: Novel targets for tuberculosis drug discovery. Curr. Opin. Pharmacol. (2006) 6:459-467.
   PubMed Web of Science ®Google Scholar
• DUNCAN K: Identification and validation of novel drug targets in tuberculosis. Curr. Pharm. Des. (2004) 10:3185-3194.
   PubMed Web of Science ®Google Scholar
• KHASNOBIS S, ESCUYER VE, CHATTERJEE D: Emerging therapeutic targets in tuberculosis: post-genomic era. Expert Opin. Ther. Targets (2002) 6:21-40.
   PubMedGoogle Scholar
• HASAN S, DAUGELAT S, RAO PS, SCHREIBER M: Prioritizing genomic drug targets in pathogens: application to Mycobacterium tuberculosis. PLoS Comput. Biol. (2006) 2:e61.
   PubMed Web of Science ®Google Scholar
• CHAKHAIYAR P, HASNAIN SE: Defining the mandate of tuberculosis research in a postgenomic era. Med. Princ. Pract. (2004) 13:177-184.
   PubMed Web of Science ®Google Scholar
• CARDONA PJ, RUIZ-MANZANO J: On the nature of Mycobacterium tuberculosis-latent bacilli. Eur. Respir. J. (2004) 24:1044-1051.
   PubMed Web of Science ®Google Scholar
• MITCHISON DA: Clinical development of anti-tuberculosis drugs. J. Antimicrob. Chemother. (2006) 58:494-495.
   PubMed Web of Science ®Google Scholar
• GINSBERG AM, SPIGELMAN M: Challenges in tuberculosis drug research and development. Nat. Med. (2007) 13:290-294.
   PubMed Web of Science ®Google Scholar
• TOIT LC, PILLAY V, DANCKWERTS MP: Tuberculosis chemotherapy: current drug delivery approaches. Respir. Res. (2006) 7:118.
   PubMed Web of Science ®Google Scholar
• ANDRIES K, VERHASSELT P, GUILLEMONT J et al.: A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science (2005) 307:223-227.
   PubMed Web of Science ®Google Scholar
• PETRELLA S, CAMBAU E, CHAUFFOUR A, ANDRIES K, JARLIER V, SOUGAKOFF W: Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria. Antimicrob. Agents Chemother. (2006) 50:2853-2856.
   PubMed Web of Science ®Google Scholar
• LOUNIS N, VEZIRIS N, CHAUFFOUR A, TRUFFOT-PERNOT C, ANDRIES K, JARLIER V: Combinations of R207910 with drugs used to treat MDR-TB have the potential to shorten treatment duration. Antimicrob. Agents Chemother. (2006) 11:3543-3547.
   Google Scholar
• IBRAHIM M, ANDRIES K, LOUNIS N et al.: Synergistic activity of R207910 combined with pyrazinamide in murine tuberculosis. Antimicrob. Agents Chemother. (2006) Dec 18: Epub ahead of print.
   Google Scholar
• GILLESPIE SH, GOSLING RD, CHARALAMBOUS BM: A reiterative method for calculating the early bactericidal activity of antituberculosis drugs. Am. J. Respir. Crit. Care Med. (2002) 166:31-35.
   PubMed Web of Science ®Google Scholar
• MCNEELEY D, CAVALIERI M: TMC 207 oral presentation. TBTC 17th Semi-Annual Group Meeting. San Diego, CA (2005).
   Google Scholar
• ASHTEKAR DR, COSTA-PERIRA R, NAGRAJAN K, VISHVANATHAN N, BHATT AD, RITFLEL W: In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. (1993) 37:183-186.
   PubMed Web of Science ®Google Scholar
• BARRY CE, BOSHOFF HI, DOWD CS: Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis. Curr. Pharm. Des. (2004) 10:3239-3262.
   PubMed Web of Science ®Google Scholar
• CHOI KP, BAIR TB, BAE YM, DANIELS L: Use of transposon Tn5367 mutagenesis and a nitroimidazopyran-based selection system to demonstrate a requirement for fbiA and fbiB in coenzyme F(420) biosynthesis by Mycobacterium bovis BCG. J. Bacteriol. (2001) 183:7058-7066.
   PubMed Web of Science ®Google Scholar
• CHOI K, KENDRICK N, DANIELS L: Demonstration that fbiC is required by Mycobacterium bovis BCG for coenzyme F(420) and FO biosynthesis. J. Bacteriol. (2002) 184:2420-2428.
   PubMed Web of Science ®Google Scholar
• STOVER CK, WARRENER P, VANDEVANTER DR et al.: A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature (2000) 405:962-966.
   PubMed Web of Science ®Google Scholar
• MANJUNATHA UH, BOSHOFF HI, DOWD CS et al.: Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA (2006) 103:431-436.
   PubMed Web of Science ®Google Scholar
• LENAERTS AJ, GRUPPO V, MARIETTA KS et al.: Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob. Agents Chemother. (2005) 49:2294-2301.
   PubMed Web of Science ®Google Scholar
• LILLIBRIDGE JH, NYWALL CS, SHAWAR RM, SLATTERY JT: PA-824, a nitroimidazopyran antitubercular agent: favorable pharmacokinetics parameters in mice after delivery in a novel oral formulation. 36th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). New Orleans, Louisiana (1996).
   Google Scholar
• NUERMBERGER E, ROSENTHAL I, TYAGI S et al.: Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob. Agents Chemother. (2006) 50:2621-2625.
   PubMed Web of Science ®Google Scholar
• TYAGI S, NUERMBERGER E, YOSHIMATSU T et al.: Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob. Agents Chemother. (2005) 49:2289-2293.
   PubMed Web of Science ®Google Scholar
• NUERMBERGER E, TYAGI S, WILLIAMS KN, ROSENTHAL I, BISHAI WR, GROSSET JH: Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model. Am. J. Respir. Crit. Care Med. (2005) 172:1452-1456.
   PubMed Web of Science ®Google Scholar
• SASAKI H, HARAGUCHI Y, ITOTANI M et al.: Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles. J. Med. Chem. (2006) 49:7854-7860.
   PubMed Web of Science ®Google Scholar
• MATSUMOTO M, HASHIZUME H, TOMISHIGE TH et al.: OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. (2006) 3:e466.
   PubMed Web of Science ®Google Scholar
• MIYAMOTO G, SHIMOKAWA Y, ITOSE M, KOGA T, HIRAO Y, KASHIYAMA E: Unique PK profile of OPC-67683, a new potent anti-tuberculosis drug. 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington DC (2005).
   Google Scholar
• DEIDDA D, LAMPIS G, FIORAVANTI R et al.: Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic Mycobacterium tuberculosis strains. Antimicrob. Agents Chemother. (1998) 42:3035-3037.
   PubMed Web of Science ®Google Scholar
• ARORA SK: Indian R&D 2006-“Mind to market”. Federation of Indian Chambers of Commerce and Industry. New Delhi (2006).
   Google Scholar
• ARORA SK, NEELIMA S, RAKESH S, RAMAN B, SHARAD S, RAM SU: Design, synthesis, modelling and activity of novel anti tubercular compounds. 227th American Chemical Society National Meeting. Anaheim CA (2004).
   Google Scholar
• SINHA RK, ARORA SK, SINHA N, MODAK VM: In vivo activity of LL4858 against Mycobacterium tuberculosis. 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC (2004).
   Google Scholar
• SPIGELMAN M, GILLESPIE S: Tuberculosis drug development pipeline: progress and hope. Lancet (2006) 367:945-947.
   PubMed Web of Science ®Google Scholar
• PROTOPOPOVA M, HANRAHAN C, NIKONENKO B et al.: Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J. Antimicrob. Chemother. (2005) 56:968-974.
   PubMed Web of Science ®Google Scholar
• JIA L, TOMASZEWSKI JE, HANRANHAN C et al.: Pharmacodynamics and pharmacokinetics of SQ-109, a new diamine-based antituberclar drug. Br. J. Pharmacol. (2005) 144:80-87.
   PubMed Web of Science ®Google Scholar
• NIKONENKO BV, PROTOPOPOVA M, SAMALA R, EINCK L, NACY CA: Drug therapy of experimental TB: improved outcome by combining SQ109, new diamine antibiotic, with existing TB drugs. Antimicrob. Agent. Chemother. (2007) Jan: [Epub ahead of print].
   Google Scholar
• JONES PB, PARRISH NM, HOUSTON TA et al.: A new class of antituberculosis agents. J. Med. Chem. (2000) 43:3304-3314.
   PubMed Web of Science ®Google Scholar
• PARRISH NM, HOUSTON T, JONES PB, TOWNSEND C, DICK JD: In vitro activity of a novel antimycobacterial compound, N-octanesulfonylacetamide, and its effects on lipid and mycolic acid synthesis. Antimicrob. Agents Chemother. (2001) 45:1143-1150.
   PubMed Web of Science ®Google Scholar
• PARRISH NM, KO CG, HUGHES MA, TOWNSEND CA, DICK JD: Effect of noctanesulphonylacetamide (OSA) on ATP and protein expression in Mycobacterium bovis BCG. J. Antimicrob. Chemother. (2004) 54:722-729.
   PubMed Web of Science ®Google Scholar
• ZURENKO GE, GIBSON JK, SHINABARGER DL et al.: Oxazolidinones: a new class of antibacterials. Curr. Opin. Pharmacol. (2001) 1:470-476.
   PubMedGoogle Scholar
• SHINABARGER D: Mechanism of action of the oxazolidinone antibacterial agents. Expert Opin. Investig. Drugs (1999) 8:1195-1202.
   PubMedGoogle Scholar
• ALCALA L, RUIZ-SERRANO MJ, PEREZ-FERNANDEZ CT et al.: In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob. Agents Chemother. (2003) 47:416-417.
   PubMed Web of Science ®Google Scholar
• TATO M, PEDROSA EG, CANTON R et al.: In vitro activity of linezolid against Mycobacterium tuberculosis complex, including multidrug-resistant Mycobacterium bovis isolates. Int. J. Antimicrob. Agents (2006) 28:75-78.
   PubMed Web of Science ®Google Scholar
• CYNAMON MH, KLEMENS SP, SHARPE CA, CHASE S: Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob. Agents Chemother. (1999) 43:1189-1191.
   PubMed Web of Science ®Google Scholar
• MOLICOTTI P, ORTU S, BUA A: In vitro efficacy of Linezolid on clinical strains of Mycobacterium tuberculosis and other mycobacteria. New Microbiol. (2006) 29:275-280.
   PubMed Web of Science ®Google Scholar
• SOOD R, BHADAURIYA T, RAO M et al.: Antimycobacterial activities of oxazolidinones: a review. Infect. Disord. Drug Targets (2006) 6:343-354.
   PubMedGoogle Scholar
• PARK IN, HONG SB, OH YM et al.: Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J. Antimicrob. Chemother. (2006) 58:701-704.
   PubMed Web of Science ®Google Scholar
• VON DER LIPPE B, SANDVEN P, BRUBAKK O: Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB) – a report of ten cases. J. Infect. (2006) 52:92-96.
   PubMed Web of Science ®Google Scholar
• FORTUN J, MARTIN-DAVILA P, NAVAS E et al.: Linezolid for the treatment of multidrug-resistant tuberculosis. J. Antimicrob. Chemother. (2005) 56:180-185.
   PubMed Web of Science ®Google Scholar
• SOOD R, RAO M, SINGHAL S, RATTAN A: Activity of RBx 7644 and RBx 8700, new investigational oxazolidinones, against Mycobacterium tuberculosis infected murine macrophages. Int. J. Antimicrob. Agents (2005) 25:464-468.
   PubMed Web of Science ®Google Scholar
• RAO M, SOOD R, MALHOTRA S, FATMA T, UPADHYAY DJ, RATTAN A: In vitro bactericidal activity of oxazolidinone, RBx 8700 against Mycobacterium tuberculosis and Mycobacterium avium complex. J. Chemother. (2006) 18:144-150.
   PubMed Web of Science ®Google Scholar
• VERA-CABRERA L, GONZALEZ E, RENDON A et al.: In vitro activities of DA-7157 and DA-7218 against Mycobacterium tuberculosis and Nocardia brasiliensis. Antimicrob. Agents Chemother. (2006) 50:3170-3172.
   PubMed Web of Science ®Google Scholar
• VERA-CABRERA L, CASTRO-GARZA J, RENDON A et al.: In vitro susceptibility of Mycobacterium tuberculosis clinical isolates to garenoxacin and DA-7867. Antimicrob. Agents Chemother. (2005) 49:4351-4353.
   PubMed Web of Science ®Google Scholar
• POTKAR C, GOGTAY N, GOKHALE P et al.: Phase I pharmacokinetic study of a new 3-azinomethyl-rifamycin (rifametane) as compared to rifampicin. Chemotherapy (1999) 45:147-153.
   PubMed Web of Science ®Google Scholar
• KELKAR MS, SARAF AP, BAKHLE DS et al.: Pharmacokinetic profile of a new 3-azinomethyl rifamycin (SPA-S-565) in volunteers as compared with conventional rifampicin. Int. J. Clin. Pharm. Res. (1998) 18:137-143.
   PubMedGoogle Scholar
• PARK-WYLLIE LY, JUURLINK DN, KOPP A et al.: Outpatient gatifloxacin therapy and dysglycemia in older adults. N. Engl. J. Med. (2006) 354:1352-1361.
   PubMed Web of Science ®Google Scholar
• AUBRY A, PAN XS, FISHER LM, JARLIER V, CAMBAU E: Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. Antimicrob. Agents Chemother. (2004) 48:1281-1288.
   PubMed Web of Science ®Google Scholar
• ONODERA Y, TANAKA M, SATO K: Inhibitory activity of quinolones against DNA gyrase of Mycobacterium tuberculosis. J. Antimicrob. Chemother. (2001) 47:447-450.
   PubMed Web of Science ®Google Scholar
• GINSBURG AS, GROSSET JH, BISHAI WR: Fluoroquinolones, tuberculosis, and resistance. Lancet Infect. Dis. (2003) 3:432-442.
   PubMed Web of Science ®Google Scholar
• FLAMM RK, VOJTKO C, CHU DT et al.: In vitro evaluation of ABT-719, a novel DNA gyrase inhibitor. Antimicrob. Agents Chemother. (1995) 39:964-970.
   PubMed Web of Science ®Google Scholar
• KIM OK, BARRETT JF, OHEMENG K: Advances in DNA gyrase inhibitors. Expert Opin. Investig. Drugs (2001) 10:199-212.
   Google Scholar
• LI Q, MITSCHER LA, SHEN LL: The 2-pyridone antibacterial agents: bacterial topoisomerase inhibitors. Med. Res. Rev. (2000) 20:231-293.
   PubMed Web of Science ®Google Scholar
• OLEKSIJEW A, MEULBROEK J, EWING P et al.: In vivo efficacy of ABT-255 against drug-sensitive and -resistant Mycobacterium tuberculosis strains. Antimicrob. Agents Chemother. (1998) 42:2674-2677.
   PubMed Web of Science ®Google Scholar
• LENAERTS AJ, GRUPPO V, MARIETTA KS, JOHNSON CM, ORME IM: Preclinical testing of the quinolone KRQ-10018 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA (2006).
   Google Scholar
• DOI N, DISRATTHAKIT A, OGISO S, SUOYAMA S, KUROSAKA Y: In vivo efficacy of DC-159a, a new generation quinolone, against experimental murine tuberculosis due to MDR-TB. 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA (2006).
   Google Scholar
• ROYCHOUDHURY S, LEDOUSSAL B: Non-fluorinated quinolones (NFQs): new antibacterials with unique properties against quinolone-resistant gram-positive pathogens. Curr. Drug Targets Infect. Disord. (2002) 2:51-65.
   PubMedGoogle Scholar
• MITNICK C, BAYONA J, PALACIOS E et al.: Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N. Engl. J. Med. (2003) 348:119-128.
   PubMed Web of Science ®Google Scholar
• WEISBLUM B: Inducible resistance to macrolides, lincosamides and streptogramin type B antibiotics: the resistance phenotype, its biological diversity, and structural elements that regulate expression – a review. J. Antimicrob. Chemother. (1985) 16:S63-S90.
   PubMed Web of Science ®Google Scholar
• MADSEN CT, JAKOBSEN L, BURIANKOVA K, DOUCET-POPULAIRE F, PERNODET JL, DOUTHWAITE S: Methyltransferase erm(37) slips on rRNA to confer atypical resistance in Mycobacterium tuberculosis. J. Biol. Chem. (2005) 280:38942-38947.
   PubMed Web of Science ®Google Scholar
• ANDINI N, NASH KA: Intrinsic macrolide resistance of the Mycobacterium tuberculosis complex is inducible. Antimicrob. Agents Chemother. (2006) 50:2560-2562.
   PubMed Web of Science ®Google Scholar
• FALZARI K, ZHU Z, PAN D, LIU H, HONGMANEE P, FRANZBLAU SG: In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. (2005) 49:1447-1454.
   PubMed Web of Science ®Google Scholar
• KOGA T, FUKUOKA T, DOI N et al.: Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo. J. Antimicrob. Chemother. (2004) 54:755-760.
   PubMed Web of Science ®Google Scholar
• WALBURGER A, KOUL A, FERRARI G et al.: Protein kinase G from pathogenic mycobacteria promotes survival within macrophages. Science (2004) 18:1800-1804.
   Google Scholar
• SCHLüNZEN F, PYETAN E, FUCINI P, YONATH A, HARMS JM: Inhibition of peptide bond formation by pleuromutilins: the structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin. Mol. Microbiol. (2004) 54:1287-1294.
   PubMed Web of Science ®Google Scholar
• ORTEGA F, MORENO R, GUIJARRO L, GARGALLO D, FERRER S: Preliminary pharmacokinetics characterization of a new class of compounds active against Mycobacterium tuberculosis. 28th Congress of the Spanish Society of Pharmacology. Santiago de Compostela, Spain (2006).
   Google Scholar
• SUN Z, ZHANG Y: Antituberculosis activity of certain antifungal and antihelmintic drugs. Tuber. Lung Dis. (1999) 79:319-320.
   PubMedGoogle Scholar
• MURUGASU-OEI B, DICK T: Bactericidal activity of nitrofurans against growing and dormant Mycobacterium bovis BCG. J. Antimicrob. Chemother. (2000) 46:917-919.
   PubMed Web of Science ®Google Scholar
• TANGALLAPALLY RP, YENDAPALLY R, LEE RE et al.: Synthesis and evaluation of nitrofuranylamides as novel antituberculosis agents. J. Med. Chem. (2004) 47:5276-5283.
   PubMed Web of Science ®Google Scholar
• CYNAMON MH, ALVIREZ-FREITES E, YEO AE: BB-3497, a peptide deformylase inhibitor, is active against Mycobacterium tuberculosis. J. Antimicrob. Chemother. (2004) 53:403-405.
   PubMed Web of Science ®Google Scholar
• TEO JW, THAYALAN P, BEER D et al.: Peptide deformylase inhibitors as potent antimycobacterial agents. Antimicrob. Agents Chemother. (2006) 50:3665-3673.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, MITCHISON DA: The curious characteristics of pyrazinamide: a review. Int. J. Tuberc. Lung Dis. (2003) 7:6-21.
   PubMed Web of Science ®Google Scholar
• DOUGLAS JD, SENIOR SJ, MOREHOUSE C: Analogues of thiolactomycin: potential drugs with enhanced anti-mycobacterial activity. Microbiology (2002) 148:3101-3109.
   PubMed Web of Science ®Google Scholar
• KIMURA K, BUGG TD: Recent advances in antimicrobial nucleoside antibiotics targeting cell wall biosynthesis. Nat. Prod. Rep. (2003) 20:252-273.
   PubMed Web of Science ®Google Scholar